

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:

Claim 1 (currently amended): A pancreatic carcinoma-specific antigen 3C4-Ag primarily localized on the surface of rat and human pancreatic cancer cells but not detected in normal, non-proliferating cells and also present in the sera or other bodily fluids of pancreatic cancer patients but not present in sera or other bodily fluids of healthy individuals, said carcinoma-specific antigen in substantially purified form and characterized by:

a molecular weight of about 43.5 kDa as determined by SDS-PAGE;

a pI on isoelectr[[o]]ic focusing of about 4.5 to about 5.0; and

being unglycosylated or minimally glycosylated; and

being said characteristics corresponding to the pancreatic-specific carcinoma as found primarily localized on the surface of rat and human pancreatic cancer cells but not detected in normal, non-proliferating cells; and said carcinoma-specific antigen characterized by a molecular weight of about 36 to about 38 kDa as determined by SDS-PAGE when isolated from sera or other bodily fluids of pancreatic cancer patients.

Claim 2 (cancel)

Claim 3 (original): An immunologically active fragment of the pancreatic carcinoma-specific antigen 3C4-Ag of claim 1.

Claim 4 (withdrawn) An antibody or binding portion thereof, having binding specificity to pancreatic carcinoma specific antigen 3C4-Ag, wherein said antigen is characterized by:

a molecular weight of about 43 kDa as determined by SDS-PAGE;

a pI on isoelectrofocusing of about 4.5 to about 5.0;

being unglycosylated or minimally glycosylated; and

being primarily localized on the surface of rat and human pancreatic cancer cells but not detected in normal, non-proliferating cells.

Claim 5 (withdrawn): The antibody of binding portion thereof, of claim 4 which also binds to a soluble pancreatic carcinoma-specific antigen having a molecular weight of about 36 to

about 38 kD as determined by SDS-PAGE and isolatable from sera and other bodily fluids of pancreatic cancer patients.

Claim 6 (withdrawn); The antibody of Claim 4 or 5 which is a polyclonal antibody.

Claim 7 (withdrawn):The antibody of claim 4 or 5 which is a monoclonal antibody.

Claim 8 (withdrawn): A murine hybridoma cell line which produces a monoclonal antibody specifically immunoreactive with the 3C4-Ag antigen of Claim 1 or 2.

Claim 9 (withdrawn): A murine hybridoma cell line which produces the monoclonal antibody of Claim 4.

Claim 10 (withdrawn): A monoclonal antibody, mAb34C, secreted by the hybridoma cell line of Claim 9.

Claim 11 (withdrawn): The monoclonal antibody mAb3C4 of claim 7 or 10 in a humanized form.

Claim 12 (withdrawn): An antibody according to claim 4 or 5 wherein the antibody is labeled with a fluorophore, chemilophore, chemiluminecer, photosensitizer, suspended particles, radioisotope or enzyme.

Claim 13 (withdrawn): An antibody according to claim 10 wherein the antibody is labeled with a fluorophore, chemilophore, chemiluminecer, photosensitizer, suspended particles, radioisotope or enzyme.

Claim 14 (withdrawn):An antibody according to claim 4 or 5 wherein the antibody is conjugated or linked to a therapeutic drug or toxin.

Claim 15 (withdrawn): The antibody of claim 14 wherein the therapeutic drug or toxin is a peptide at least about six contiguous amino acids of the amino sequence set forth in SEQ PPLSQETFSDLWKLL (SEQ ID NO:1) or an analog or derivative thereof.

Claim 16 (withdrawn): The antibody of claim 15 wherein the penetratin sequence from *antennapedia* protein having the amino acid sequence KKWKMRRNQFWVKVQRG (SEQ ID NO:4) is positioned at the carboxy terminal end of the peptide.

Claim 17 (withdrawn): An antibody according to claim 10 wherein the antibody is conjugated or linked to a therapeutic drug or toxin.

Claim 18 (withdrawn): A method of detecting pancreatic cancer in an animal subject, said method comprising the steps of:

- (a) contacting a cell, tissue or fluid sample from the subject with at least one of an antibody or binding portion thereof which specifically binds to 3C4-Ag or an immunologically active fragment thereof; the monoclonal antibody mAb34C; or an antibody which binds the epitope bound by the monoclonal antibody mAb34C; under conditions permitting said antibody to specifically bind an antigen in the sample to form an antibody-antigen complex;
- (b) detecting antibody-antigen complex in the sample; and
- (c) correlating the detection of elevated levels of antibody-antigen complex in the sample with the presence of pancreatic cancer.

Claim 19 (withdrawn): A diagnostic kit suitable for detecting 3C4-Ag in a cell, tissue, or fluid sample from a patient, said kit comprising:

- (a) an antibody or binding portion thereof which specifically binds 3C4-Ag or an immunologically active fragment thereof,
- (b) a conjugate of a specific binding partner for the antibody or binding portion thereof; and
- (c) a label for detecting the bound antibody.

Claim 20 (withdrawn): A method of treating pancreatic cancer in a patient suffering therefrom which comprises administering to the patient an effective amount of an antibody or binding portion thereof which specifically binds to 3C4-Ag or an immunologically active fragment thereof, wherein said antibody or binding portion thereof is conjugated or linked to a therapeutic drug or toxin.

Claim 21 (withdrawn): The method of claim 20 wherein said antibody is mAb3C4.

Claim 22 (withdrawn): The method of claim 20 or 21 wherein the therapeutic drug or toxin is a peptide of at least about six contiguous amino acids of the amino sequence set forth in SEQ PPLSQETFSDLWKLL (SEQ ID NO:1) or an analog or derivative thereof.

Claim 23 (withdrawn): A pharmaceutical composition comprising an antibody or binding portion thereof which specifically binds to 3C4-Ag, admixed with a pharmaceutically acceptable carrier.

Claim 24 (withdrawn): The pharmaceutical composition of claim 23 wherein the antibody or binding portion thereof which specifically binds to 3C4-Ag is conjugated or linked to a therapeutic drug or toxin.